Last reviewed · How we verify

Primary hypogonadism — Treatment Landscape & Competitive Intelligence

Primary hypogonadism (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Primary hypogonadism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tlando UNDECANOATE Tolmar 2025-01-01
Aveed TESTOSTERONE UNDECANOATE Marius Androgen Androgen receptor 2014-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Marius · 1 drug in Primary hypogonadism
  2. Tolmar · 1 drug in Primary hypogonadism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Primary hypogonadism:

Cite this brief

Drug Landscape (2026). Primary hypogonadism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-hypogonadism. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing